体重指数、中心性肥胖与减重对替尔泊肽治疗HFpEF获益的影响:SUMMIT试验
SUMMIT试验纳入731例肥胖相关HFpEF患者,随机接受替尔泊肽或安慰剂。分析显示,基线BMI越高者更年轻、女性更多、心衰更重且炎症更明显;替尔泊肽降低心衰恶化或心血管死亡风险不受BMI或腰高比影响,但基线BMI越高者6分钟步行距离改善越大,且减重越多与6分钟步行距离和KCCQ改善越明显相关。
要点
- 替尔泊肽降低HFpEF患者心衰恶化或心血管死亡风险不受基线BMI或腰高比影响。
- 基线BMI越高,替尔泊肽对6分钟步行距离的改善越明显。
- 替尔泊肽治疗中减重越多,6分钟步行距离和KCCQ改善越大。
核心结论
- 在肥胖相关HFpEF患者中,替尔泊肽降低心衰恶化或心血管死亡风险的效果不受基线BMI或腰高比影响。
- 基线BMI越高者,替尔泊肽对6分钟步行距离的改善越明显。
- 替尔泊肽治疗中减重越多,6分钟步行距离和KCCQ改善越大。
研究设计与样本
- SUMMIT试验为随机双盲安慰剂对照试验,纳入731例NYHA II-IV级、BMI≥30 kg/m2的HFpEF患者,替尔泊肽组364例,安慰剂组367例。
- 本次为二次分析,按基线BMI和腰高比三分位分组,分析主要终点(心血管死亡或心衰恶化时间、52周KCCQ-CSS变化)及关键次要终点。
- 时间事件终点采用Cox回归模型,连续终点采用混合效应模型重复测量。
主要发现
- 基线BMI越高者更年轻、女性比例更高、心衰症状和体力受限更重、容量负荷更明显、炎症更重,但利钠肽水平更低。
- 腰高比越高者与BMI越高者特征相似,但运动能力更差、肾脏病更重。
- 替尔泊肽对心衰恶化或心血管死亡风险的影响按BMI或腰高比三分位无显著异质性。
- 随基线BMI三分位升高,替尔泊肽组6分钟步行距离改善更大(估计治疗差异:9.9 vs 26.3 vs 37.5 m;P=0.025)。
- 随基线BMI三分位升高,替尔泊肽组体重下降(估计治疗差异:-10.7% vs -11.8% vs -14.4%;P=0.006)和收缩压下降(估计治疗差异:-1.00 vs -6.65 vs -6.62 mm Hg;P=0.035)更明显,KCCQ-CSS改善有趋势(P=0.097)。
临床怎么用
- 对于肥胖相关HFpEF患者,替尔泊肽的心衰获益不受基线BMI或腰高比影响,高BMI患者同样可获益。
- 基线BMI较高的患者可能从替尔泊肽获得更明显的运动能力和体重改善。
- 替尔泊肽治疗中减重越多,运动能力和生活质量改善越明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide 1 receptor agonist tirzepatide decreased the risk of cardiovascular death or worsening heart failure (HF) in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Effects may differ by baseline obesity severity, distribution, or magnitude of weight loss. OBJECTIVES: In this analysis, the authors compared baseline characteristics and effects of tirzepatide on primary and other endpoints according to baseline obesity severity and distribution, and we explored relationships between degree of weight loss achieved and outcomes. METHODS: In the SUMMIT trial, 731 patients with NYHA functional class II-IV HFpEF and body mass index (BMI) ≥30 kg/m2 were randomly assigned to tirzepatide (n = 364) or placebo (n = 367). The primary outcomes were time to cardiovascular death or worsening HF and change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at 52 weeks. Key secondary outcomes included changes in 6-minute walk distance (6MWD), C-reactive protein (CRP), and body weight (BW) at 52 weeks. In this secondary analysis, primary and secondary endpoints were analyzed based on obesity severity (BMI) and distribution (waist-height ratio [WHR]). Time-to-event endpoints were analyzed with the use of a Cox regression model, and continuous endpoints were assessed with the use of a mixed-effects model for repeated measures. Relationships between changes in BW and waist circumference (WC) on treatment with tirzepatide and changes in key endpoints also were evaluated. RESULTS: Patients with obesity-related HFpEF and higher BMI were younger and more likely to be female, with more severe HF symptoms and physical limitations, greater volume expansion despite higher diuretic use and lower natriuretic peptide levels, and more severe systemic inflammation compared with patients with lower BMI. These findings were largely similar when contrasting patients by baseline WHR, but those with higher WHR also had poorer exercise capacity and more severe kidney disease. There was no evidence of heterogeneity in the effect of tirzepatide on the risk of worsening HF or cardiovascular death by BMI or WHR tertile. However, with increasing tertiles of baseline BMI, there were greater improvements in 6MWD (estimated treatment difference [ETD]: 9.9 vs 26.3 vs 37.5 m; P = 0.025), and greater decreases in BW (ETD: -10.7% vs -11.8% vs -14.4%; P = 0.006) and systolic blood pressure (ETD: -1.00 vs -6.65 vs -6.62 mm Hg; P = 0.035) with tirzepatide compared with placebo, with a trend for greater improvement in KCCQ-CSS (P = 0.097). Among those randomized to tirzepatide, greater weight loss at 52 weeks was associated with larger improvements in 6MWD, KCCQ-CSS, CRP, and blood pressure, and a greater decrease in WC was associated with larger increases in 6MWD and KCCQ-CSS. Patients with elevated WHR but lower BMI had higher NYHA functional class and N-terminal pro-B-type natriuretic peptide, poorer kidney function, and lower 6MWD compared with those with lower WHR but higher BMI. CONCLUSIONS: Among patients with obesity-related HFpEF, greater BMI is associated with younger age, female sex, more volume overload and inflammation, and more severe HF, and those with greater WHR also showed greater impairment in kidney function and exercise capacity. Tirzepatide consistently reduced the risk of HF or cardiovascular death regardless of baseline BMI, but there was evidence suggesting greater improvement in 6MWD in those with higher BMI at baseline. Greater weight loss on treatment with tirzepatide was associated with greater improvements in 6MWD and KCCQ. (A Study of Tirzepatide [LY3298176] in Participants With Heart Failure With Preserved Ejection Fraction [HfpEF] and Obesity [SUMMIT]; NCT04847557).
引用
- Borlaug BA, Zile MR, Kramer CM, et al. Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial. J Am Coll Cardiol. 2025. PMID: 40701669. doi:10.1016/j.jacc.2025.04.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。